Animal NDC 86106-0225-3 Posilac
Sometribove

Animal Product Information

Field Name Field Value
Animal NDC Code 86106-0225-3
Proprietary Name Posilac What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name Sometribove What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
Labeler Name Union Agener Inc
Product Type Otc Animal Drug
Usage Information
    USE: To increase production of marketable milk in healthy lactating dairy cows.
Active Ingredient(s)
  • Sometribove
Inactive Ingredient(s)
  • SESAME OIL (QX10HYY4QV)
  • ALUMINUM MONOSTEARATE (P9BC99461E)
  • SESAME OIL (QX10HYY4QV)
  • ALUMINUM MONOSTEARATE (P9BC99461E)
Marketing Category NADA - NEW ANIMAL DRUG APPLICATION What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number NADA140872 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Posilac Animal Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Table of Contents



Other



Posilac (sometribove zinc suspension)

CAUTION: Federal law prohibits extra-label use of this drug to enhance food and/or fiber production in animals.

INJECTION TECHNIQUE: Inject Posilac subcutaneously (under the skin). Recommended injection sites are neck area, behind the shoulder or in the depression on either side of the tailhead (see diagrams below). Alternate between the cow's left and right side on consecutive injections. Remove surface dirt from the injection site area before injecting. Inject entire contents of the syringe subcutaneously. Do not reuse syringes.

Inject directly into the deepest depressions on either side of the tailhead (marked "Yes"). Avoid the bone, muscles, tendons and ligaments of the tail and the rectal and anal muscles. Do NOT inject into the caudal fold (marked "No") because this may invalidate USDA tuberculosis testing. Locate the caudal fold by raising the tail.

  • Reproduction: Cows injected with Posilac may have reduced pregnancy rates and increased days open. Have a comprehensive and ongoing herd reproductive health program In place on your dairy before using Posilac.
    • Mastitis: Cows injected with Posilac are at an increased risk of mastitis (visibly abnormal milk) and may have higher somatic cell counts. Have comprehensive mastitis management practices in place on your dairy before using Posilac.
      • General Health: Cows injected with Posilac may require more therapeutic drug treatment for mastitis and other health problems. Cows injected with Posilac may experience periods of increased body temperature unrelated to illness. To minimize the effect, take appropriate measures during periods of high environmental temperature to reduce heat stress. Use care to differentiate whether increased body temperature is caused by illness or use of Posilac. Cows injected with Posilac may have more enlarged hocks and disorders of the foot region. Posilac treatment may reduce hemoglobin and hematocrit values.
        • Injection Site Reactions: A mild temporary swelling of 3-5 cm (1-2 inches) in diameter may occur at the injection site beginning about 3 days after injection and may persist up to 6 weeks following injection. Larger swellings may occur in cows injected in the neck area compared to the behind the shoulder or in the depression on either side of the tailhead. Some cows may experience swellings up to 10 cm (4 inches) in diameter that remain permanent but are not associated with animal health problems. However, if permanent blemishes are objectionable to you, stop supplementation of these cows. Also stop using Posilac in cows with injection site swellings that repeatedly open and drain.
          • Udder Edema: Posilac is approved for use starting during the 9th or 10th week of lactation. Risk of udder edema may increase if injections start later in lactation.

Description



DESCRIPTION: Sterile, prolonged-release injectable formulation of a recombinant DNA-derived bovine somatotropin analog in single-dose syringes each containing 500 mg of sometribove zinc.


Indications & Usage



USE: To increase production of marketable milk in healthy lactating dairy cows.


Dosage & Administration



DOSAGE: Inject one syringe of Posilac every 14 days. Start during the 9th or 10th week (57-70 days) after calving and continue until the end of lactation.

ADMINISTRATION: Allow syringes to warm to room temperature (15° to 30° C, 59° to 86° F) before use.


Injection Sites:



Tailhead DepressionNeck & Behind The Shoulder

Gather skin and inject between skin and muscle layers.
WITHDRAWAL PERIODS:
No milk discard time and no withdrawal period is required when used according to labeling.

Warnings



USER SAFETY WARNINGS: Not for use in humans, Keep out of reach of children, Avoid prolonged or repeated contact with Posilac with eyes and skin, Posilac is a protein. Frequent skin contact with proteins may produce an allergic reaction in some people. Always wash hands and skin exposed to Posilac with soap and water after handling. Clothing soiled with the product should be laundered before reuse.


Animal Safety Warnings:



  • Use in lactating dairy cows only.
  • Safety to replacement bulls born in dairy cows injected with Posilac has not been established.
  • Avoid injecting within 2 weeks of slaughter to minimize injection site blemishes on carcass.

Additional Information:



  • Milk production response during each 14-day injection period is cyclic and will be greatest during the middle of each period.

Storage And Handling



STORAGE: Store under refrigeration (2° to 8° C; 36° to 46° F). DO NOT FREEZE. Allow syringes to warm to room temperature (15° to 30° C; 59° to 86° F) before use. Avoid prolonged exposure to excessively high temperature and sunlight. Expiration dates are stated on syringes and box labeling.


Environmental Warning



ENVIRONMENTAL SAFETY: Dispose of used syringes in a leak-resistant, puncture-resistant container in accordance with applicable Federal, state, and local regulations.


How Supplied



HOW SUPPLIED: Single-dose syringes in 25 or 100 count boxes.


Questions/Comments?



Contact Union Agener, Inc. at +1 844-952-0330. To report side effects, contact Union Agener, Inc. at +1 844-952-0330. For additional information about reporting side effects for animal drugs, contact FDA at + 1 1-888-FDA-VETS or http://www.fda.gov/reportanimalae


Principal Display Panel - 25 Syringe Carton



Posilac (sometribova suspensión de zinc)

Mantener en refrigeración (2 °C a 8 °C; 36° F a 46 °F). NO CONGELAR. Permita que las jeringas alcancen la temperatura ambiente
(15 °C a 30 °C; 59 ° a 86 °F) antes de usar. Evite la exposición prolongada a temperaturas excesivamente altas y a la luz solar.

Elaborado por
Union Agener, Inc.
1788 Lovers Lane, Augusta, Georgia 30901, EUA

¿PREGUNTAS/COMENTARIOS?

Conctate a Union Agener, Inc. al +1 844-952-0330. Para reportar efectos secundarios, conctate Union Agener, Inc.: +1 844-952-0330. Para obtener informaciones
adicionales sobre cómo reportar efectos secundarios de medicamentos para animales, conctate FDA +1 1-888-FDA-VETS o http://www.fda.gov/reportanimalae

Aprobado por la FDA bajo número NADA # 140-872


* The information on this page is for an ANIMAL PRODUCT, please review the complete disclaimer below.